Department of Genetics, Development and Cell Biology, Iowa State University, Ames, IA, 50011, USA.
Department of Toxicology, Faculty of Veterinary Medicine, Benha University, Qalyubia, 13518, Egypt.
Nat Commun. 2023 Nov 23;14(1):7668. doi: 10.1038/s41467-023-43349-1.
Uncovering the mechanisms regulating hematopoietic specification not only would overcome current limitations related to hematopoietic stem and progenitor cell (HSPC) transplantation, but also advance cellular immunotherapies. However, generating functional human induced pluripotent stem cell (hiPSC)-derived HSPCs and their derivatives has been elusive, necessitating a better understanding of the developmental mechanisms that trigger HSPC specification. Here, we reveal that early activation of the Nod1-Ripk2-NF-kB inflammatory pathway in endothelial cells (ECs) primes them to switch fate towards definitive hemogenic endothelium, a pre-requisite to specify HSPCs. Our genetic and chemical embryonic models show that HSPCs fail to specify in the absence of Nod1 and its downstream kinase Ripk2 due to a failure on hemogenic endothelial (HE) programming, and that small Rho GTPases coordinate the activation of this pathway. Manipulation of NOD1 in a human system of definitive hematopoietic differentiation indicates functional conservation. This work establishes the RAC1-NOD1-RIPK2-NF-kB axis as a critical intrinsic inductor that primes ECs prior to HE fate switch and HSPC specification. Manipulation of this pathway could help derive a competent HE amenable to specify functional patient specific HSPCs and their derivatives for the treatment of blood disorders.
揭示调控造血特化的机制不仅将克服与造血干/祖细胞 (HSPC) 移植相关的当前局限性,还将推进细胞免疫疗法。然而,生成功能性的人诱导多能干细胞 (hiPSC) 衍生的 HSPC 及其衍生物一直难以实现,这需要更好地理解触发 HSPC 特化的发育机制。在这里,我们揭示了内皮细胞 (EC) 中 Nod1-Ripk2-NF-kB 炎症途径的早期激活使它们能够向确定性造血内皮(指定 HSPC 的前提)转变命运。我们的遗传和化学胚胎模型表明,由于在造血内皮 (HE) 编程方面的失败,缺乏 Nod1 和其下游激酶 Ripk2 的情况下 HSPC 无法特化,并且小 Rho GTPases 协调该途径的激活。在确定性造血分化的人类系统中对 NOD1 的操纵表明了功能的保守性。这项工作确立了 RAC1-NOD1-RIPK2-NF-kB 轴作为一个关键的内在诱导物,在 HE 命运转换和 HSPC 特化之前使 EC 成熟。对该途径的操纵可能有助于获得适合指定功能性患者特异性 HSPC 及其衍生物的 HSPC,用于治疗血液疾病。